|
 Certain bacteria seem to help in cancer by priming immune cells and
smoothing the path for immunotherapy drugs known as PD-1 drugs that
work by taking the brakes off the immune system.
Seres Therapeutics hopes to become the first company to leverage
this discovery through a collaboration with the MD Anderson Cancer
Center in Texas and the Parker Institute for Cancer Immunotherapy
that will see its microbe medicine tested in a clinical trial.
The Cambridge, Massachusetts-based firm has an exclusive option to
license patent rights under the deal announced on Tuesday.
MD Anderson scientists were among two groups of cancer researchers
who reported on the benefits of good gut microbes in the journal
Science earlier this month.
The work underscores the importance of the microbiome - the vast
community of microbes living inside us - which has been linked to
everything from digestive disorders to depression.
Seres Chief Executive Roger Pomerantz told Reuters the aim was to
start the randomized, placebo-controlled clinical trial in
metastatic melanoma in 2018, evaluating the impact of giving a newly
developed Seres microbiome drug alongside a PD-1 therapy.
There are currently two approved PD-1 drugs, Merck & Co's Keytruda
or Bristol-Myers Squibb's Opdivo, but Pomerantz declined to say
which would be used.
Seres, which is backed by Swiss food giant Nestle, became the first
microbiome drug developer to go public in June 2015 but it suffered
a setback last year when its leading drug candidate failed in a
trial against C. difficile, a debilitating gut infection.
BEYOND THE GUT
Other companies are competing hard. Like Seres, some are also eyeing
the new opportunity in cancer, as microbiome science moves beyond
the initial focus on gastrointestinal conditions like C. difficile,
ulcerative colitis and inflammatory bowel disease.
Vedanta Biosciences, another U.S. biotech firm that is an affiliate
of PureTech Health, plans to file for approval to start a clinical
trial in immuno-oncology in 2018, while Synlogic is also working on
experimental cancer therapies.
[to top of second column] |
French biotech company Enterome, meanwhile, is working with
Bristol-Myers on microbiome-derived diagnostic tests and potential
drugs to use with the U.S. drugmaker's immunotherapy medicines.
"This shift makes sense," said Vedanta CEO Bernat Olle of the latest
focus on cancer.
"About 80 percent of your immune system cells are in the intestine
... but cells that are educated in the gut don't stay there. Every
day they cycle several times throughout the body and some of them
will go to tumors."
Advocates argue that microbiome medicine offers a smart way to both
tone down the immune system response - useful for conditions like
rheumatoid arthritis and allergies - or ramp it up, which is needed
for the body to fight back against cancer.
The first wave of microbiome drugs rely on faecal microbiota
transplantation (FMT), or samples of microbes distilled from human
faeces, delivered either as a capsule or by enema. But companies are
also working on synthetically fermented versions.
Seres boss Pomerantz believes microbiome science will open up a
major new treatment field, like monoclonal antibodies did when they
were pioneered by Centocor, now part of Johnson & Johnson, three
decades ago.
"Just as Centocor started monoclonals back in the 1980s, we think we
are the Centocor of the microbiome - but of course there will be
other companies."
(Reporting by Ben Hirschler; Editing by Hugh Lawson)
[© 2017 Thomson Reuters. All rights
reserved.] Copyright 2017 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
